Taysha Gene Therapies Issues Stock Grants to Four New Hires
Taysha Gene Therapies granted RSUs and stock options to four new employees under its 2023 Inducement Plan on Oct. 1, 2026.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced Thursday that its Board of Directors' Compensation Committee approved equity grants for four newly hired employees, effective October 1, 2026, as part of standard recruitment incentives allowed under Nasdaq listing rules.
The grants consist of restricted stock units representing 384,000 shares of the company's common stock and a stock option to purchase an additional 92,400 shares. Both instruments were issued under the company's 2023 Inducement Plan, a compensation structure specifically designed to attract new talent outside of shareholder-approved equity pools.
Read more Ashton Woods to Host Quarterly Earnings Call on Oct. 8 →
The awards were structured to comply with Nasdaq Listing Rule 5635(c)(4), which permits companies to grant equity as a material inducement to individuals entering new employment without obtaining prior shareholder approval, provided the grants are disclosed publicly. The rule is commonly used by clinical-stage biotechnology firms seeking to recruit specialized personnel in competitive labor markets.
Taysha is a Dallas-based, clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies targeting severe monogenic diseases of the central nervous system. The company has not disclosed the identities or roles of the four new employees receiving the grants.
Continue reading at GlobeNewswire - Industry News on Financial Services.
